Late Breaking Oral Presentation by IMMX

“We believe NXC-201’s tolerability profile, including lack of neurotoxicity, makes it uniquely suitable as a potential new treatment option for relapsed/refractory AL Amyloidosis patients.”

– Gabriel Morris, CFO, Immix Biopharma

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1:

12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs)

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data
Read More
Previous slide
Next slide


Immix Biopharma, Inc. (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases.

Learn more about how Immix Biopharma is leading the way with innovative treatments and how you can be part of this historic journey.

Sign Up For Updates to Learn More About IMMIX

Pioneering Research by Dr. Georg Schett

Leading the Way in Autoimmune Therapy

In the ever-evolving field of autoimmune disease treatment, Dr. Georg Schett stands out as a pioneering figure. His extensive work in rheumatology and innovative approach to CAR-T therapy has garnered significant attention. Recognizing the limitations and risks associated with traditional CAR-T therapies that target CD19, Dr. Schett has suggested that a BCMA-focused approach might offer an even better solution.

Why BCMA Over CD19?

Traditional CD19-targeting therapies can inadvertently destroy healthy baby B cells, posing risks to patients. Dr. Schett believes that targeting BCMA (B-cell maturation antigen) could provide a more precise and effective approach. BCMA is present on mature B cells and plasma cells, the primary culprits in many autoimmune conditions. By focusing on BCMA, therapies can aim to eliminate pathologic plasma cells without harming healthy cells, potentially enhancing both safety and efficacy.

A Vision for the Future

Dr. Schett’s insights align with the vision of Immix Biopharma, solidifying their approach with NXC-201, a therapy designed to target BCMA. This alignment underscores the potential for developing safer and more effective treatments for autoimmune diseases. Immix Biopharma’s commitment to this innovative approach marks a significant advancement in the field, offering new hope to patients who have exhausted traditional treatment options.

5 Reasons to Get on Board

Innovative Single-Day CAR-T Therapy

At the core of Immix Biopharma’s mission is NXC-201, a testament to the power of scientific innovation and dedication. Engineered for efficacy and simplicity, NXC-201 is not just a drug but a beacon of hope, offering a single-day CAR-T therapy that minimizes hospital stays and maximizes quality of life. This efficiency not only enhances patient experience but opens new doors in autoimmune and cancer treatment accessibility and affordability.

Clinical Advancements

Memorial Sloan Kettering Cancer Center was just named as lead clinical site for NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial. IMMX is actively conducting Phase I/II clinical trials for NXC-201, with plans to treat 100 patients (63 already treated at the high dose). Recent interim data has been highly promising, indicating the therapy’s potential to address challenging diseases effectively.

Multiple additional indications

IMMX’s pioneering therapy, NXC-201, initially celebrated for its groundbreaking single-day treatment of AL Amyloidosis, now stands as a beacon of hope for the broader realm of autoimmune diseases. Its success and unique mechanism of action hint at a transformative potential beyond its initial application, suggesting a versatile approach that could revolutionize treatment strategies across the autoimmune spectrum.

Market Position

IMMX has a solid presence in the biotech industry, with a market capitalization of about $75M there could be significant upside compared to its peers. The company’s focus on CAR-T technology could potentially drive future growth and market capitalization.

Comparative Analysis

When compared to other industry peers, IMMX’s dedication to cutting-edge CAR-T therapy sets it apart. IMMX’s focus on advanced biopharmaceuticals positions it as an attractive investment option for those seeking innovation and potential growth in the healthcare sector.

March 20, 2024

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

CAR-T Provides Better Outcomes For Patients

"Unleash the full potential of your immune system"

Unleash the full potential of your immune system:
The IMMX single-day CAR-T therapy harnesses the power of the patient’s own immune cells to target and destroy cancer cells, offering a personalized and highly targeted treatment option.

Say goodbye to lengthy hospital stays:
Unlike traditional CAR-T therapies, the single-day treatment allows the patient to receive the therapy in a comfortable and convenient setting, minimizing disruption to your daily life.

Experience fewer side effects:
Advanced technology ensures a more targeted approach, which may reduce the risk of severe side effects commonly associated with other cancer treatments.

Empower yourself with hope:
With a single-day CAR-T therapy, patients would be able to regain control over their life and embark on a journey towards remission, offering renewed hope for a brighter future.


Single-day CAR-T therapy, exemplified by Immix Biopharma’s NXC-201, offers a transformative shift in the landscape of autoimmune disease and cancer treatments, delivering significant financial and healthcare advantages. With a cost ranging from $1-1.5 million per patient, where the drug itself accounts for $350-450k, NXC-201 represents a more cost-effective option when compared to traditional CAR-T therapies. Notably, it slashes hospitalization costs by approximately 80%, resulting in substantial savings.

Additionally, physicians at hospitals have expressed a preference for NXC-201 due to its milder side effects, reducing the need for frequent patient calls and follow-up visits. What’s truly groundbreaking is that NXC-201 has the potential to democratize CAR-T therapy, as it can be administered in about 3 days, compared to the 14+++ days (up to 60 days) required for other CAR-T treatments. This efficiency enables the expansion of CAR-T therapy to the 95% of hospitals that were previously unable to offer it, making cutting-edge cancer care more accessible and streamlined for patients.


Introducing a Breakthrough in CAR-T Cancer Therapy!

February 8, 2024

Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock

Financing provides ample runway for clinical development. 

IMMX's mission is to harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures.

Autoimmune disease Market

$ 0

The global autoimmune disease therapeutics market is projected to grow from approximately $71.47 billion in 2023 to about $123.51 billion by 2033. (FMI Market Research)

AL R/R Patients
~ 0

There are  approximately 30,0000 relapsed/refractory AL Amyloidosis patients in the US —with NO FDA approved drugs on the market

Autoimmune Patients
0 M

In the United States, more than 23.5 million Americans are affected by autoimmune diseases, and this number is believed to be on the rise. (NIH)


  • Myastehnia Gravis
  • Neuromyelitis Optica Spectrum Disorder
  • Pemphigus Vulgaris
  • Dermatomyositis
  • Ulcerative Colitis
  • Celiac Disease
  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis
  • Al Amyloidosis
  • Waldenstrom Macroglobulinemia
  • IgA Nephropathy
  • IgM Nephropathy


Comparative Analysis of other industry peers

Arcellx (ACLX) - 3.5B Market Cap

Prothena (PRTA) - 1.37B Market Cap

“Today, CAR-T cell therapies generate greater than $3 billion of annualized sales, even though due to neurotoxicity and side effects, they are dosed in only 5% of U.S. hospitals. NXC-201 has been dosed in a large number of patients across released/refractory AL amyloidosis and relapsed/refractory multiple myeloma. We believe NXC-201 could offer hope to those on waiting lists for CAR-T cell therapies, and potentially become the first out-patient CAR-T expanding into to the remaining 95% of U.S. hospitals.”

Exceptional Advisory Board Leadership and Management

What is CAR-T Cancer Therapy?

"immune cells are taken and subjected to sophisticated laboratory reengineering, transforming them into cancer-fighting champions."

CAR-T therapies represent a pioneering frontier in the realm of cancer treatment. Picture your immune system as an elite battalion of defenders, tirelessly safeguarding your body. CAR-T, a revolutionary breakthrough, elevates this defense force to superhero status. Here’s how: A select group of your immune cells are taken and subjected to sophisticated laboratory reengineering, transforming them into cancer-fighting champions. Once reintroduced into your body, these supercells possess the remarkable ability to target and destroy cancer cells with precision, leaving your healthy cells unscathed. It’s akin to bestowing your immune system with an extraordinary upgrade, equipping it to combat cancer with unparalleled efficacy.

However, in this medical marvel, there exists a caveat. Occasionally, the infusion of CAR-T therapies can carry the risk of neurotoxicity—an intricate term for a serious issue. This condition may manifest as severe confusion, extreme fatigue, or intense headaches. In essence, your immune superheroes, driven by their unwavering dedication to vanquish cancer, may inadvertently disrupt your brain’s normal function. Regrettably, neurotoxicity can prove life-threatening for certain patients, necessitating vigilant monitoring by healthcare professionals throughout the treatment process. Consequently, patients must allocate a minimum of two weeks, and potentially several months, to hospital care to closely observe and manage this profound medical development.





Immix Biopharma (NASDAQ: IMMX) is unlocking the power of the human immune system and revolutionizing CAR-T treatments for autoimmune diseases. The groundbreaking first-of-its-kind single-day CAR-T therapy could be a major game changer and is poised to turn the entire autoimmune therapeutic market on its head!

Immix Biopharma (NASDAQ : IMMX) has harnessed cutting-edge technology and innovative approaches to create a different kind of CAR-T therapy – Single-Day CAR-T Therapy. With this groundbreaking therapy, they’ve reimagined the entire CAR-T therapy experience. The body still gets those superhero immune cells, but now you don’t have to stay in the hospital for weeks and sometimes months. The treatment is more convenient, more comfortable, and the indications point to a significantly reduced risk of severe side effects, including neurotoxicity, allowing patients to undergo treatment with greater peace of mind. 


"cutting-edge CAR-T therapy...response rate of 95% and 100%"

Immix Biopharma (NASDAQ: IMMX) is making significant strides in the field of CAR-T cell therapy. Their cutting-edge CAR-T therapy, known as NXC-201, is showing great promise in the treatment of multiple myeloma and AL amyloidosis, with impressive response rates of 95% and 100%, respectively.

Furthermore, IMMX is actively expanding its portfolio and seeking FDA approval for NXC-201 through ongoing Phase I/II trials, aiming to treat 100 patients with 63 patients already treated at the high dosage. Recent interim data for NXC-201 has been highly encouraging, positioning it as a potential breakthrough therapy in the fight against these challenging diseases.

IMMX’s dedication to advancing CAR-T technology underscores its commitment to improving patients’ lives and offers investors an opportunity to support a company at the forefront of groundbreaking treatments in the biopharmaceutical industry.

Industry leading research and development partners

World-Class Team

Ilya Rachman, MD, PhD

Dr. Rachman is a physician/scientist and former community clinical faculty at UCLA. He received both his MD and PhD from the University of Illinois, and his MBA from UCLA Anderson. Ilya founded a Clinical Research organization that conducted clinical trials of pharmaceutical drugs, and is also currently the CEO of Immix Biopharma, Inc. He has completed several clinical trials as a Principal Investigator and developed strong relationships in the clinical research industry.

Gabriel Morris

Gabriel Morris is the Chief Financial Officer of Immix Biopharma, Inc. Mr. Morris has been managing partner of Alwaysraise LLC, a life sciences advisory and investment firm based in San Francisco, since founding. Prior, Mr. Morris was the interim Chief Financial Officer of Zap Surgical Systems, a brain radiosurgery company, where he completed a growth equity financing round. Prior, Mr. Morris led cross-border mergers & acquisitions transactions at Goldman Sachs and other global investment banks for more than a decade, where he participated in greater than $50 billion in completed transactions. Mr. Morris received his B.A. from the Columbia University in the City of New York.

Graham Ross, FFPM

Dr. Ross is an experienced pharmaceutical physician executive with a successful track record of development and post-marketing activities of a number of cancer therapeutics (including topoisomerase inhibitors and therapeutic antibodies, such as immune checkpoint inhibitors and next generation immunotherapeutics). Prior, Dr. Ross was Senior Medical Science Director, AstraZeneca and Global Clinical Leader at Roche Pharmaceuticals, where he was responsible for the clinical development and registration of a drug in breast cancer indications. Prior to Roche, Dr. Ross was Director of Clinical Development at GlaxoSmithKline for a decade. Dr. Ross trained in oncology in Durban, South Africa and specialized a second time as a pharmaceutical physician in the UK.

NASDAQ : IMMX in the News


Immix Biopharma on Track to Dose NXC-201 Patients in United States


Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)


Immix Biopharma (NASDAQ : IMMX) Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial


Immix Biopharma (NASDAQ : IMMX) Announces "Be Proactive in AL" AL Amyloidosis Awareness Initiative


Immix Biopharma (NASDAQ : IMMX) 12 Month Review Progress Update


Immix Biopharma (NASDAQ : IMMX) Announces Closing of $15 Million Public Offering of Common Stock


Stay Ahead of the Curve with IMMX News & Updates!